



HHS Public Access

Author manuscript

Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 May 31.

Published in final edited form as:

Int J Tuberc Lung Dis. 2017 April 01; 21(4): 420–424. doi:10.5588/ijtld.16.0833.

Role of bacille Calmette-Guérin in preventing tuberculous infection

S. Adinarayanan^{*}, R. K. Culp[†], R. Subramani^{*}, K. M. Abbas[†], S. Radhakrishna[‡], and S. Swaminathan^{*}

^{*}National Institute for Research in Tuberculosis, Chennai, India

[†]Virginia Tech, Blacksburg, Virginia, USA

[‡]Institute for Research in Medical Statistics, Madras Chapter, Chennai, India

SUMMARY

SETTING—Rural community in South India.

OBJECTIVE—To determine the role of bacille Calmette-Guérin (BCG) in preventing tuberculous infection in children.

DESIGN—A prevalence survey was undertaken in 1999–2001 in a representative rural population in Tiruvallur District in South India using cluster sampling. Tuberculin testing was performed among all children aged <15 years, and all adults aged ≥15 years were questioned about chest symptoms and underwent radiography, followed by sputum examinations, if indicated.

RESULTS—In children living in households with a tuberculosis case, the proportion with evidence of tuberculous infection was 35.5% of 200 in the absence of a BCG scar and 27.0% of 100 in its presence, a reduction of 24% ($P=0.14$). In very young children (age <5 years), the corresponding proportions were 29.1% of 55 and 11.9% of 42, a reduction of 59%; the difference was statistically significant ($P=0.048$).

CONCLUSION—There is a possible role for BCG in preventing tuberculous infection in very young children.

Keywords

survey; tuberculous infection; BCG; epidemiology; community

Several Randomised Trials have been undertaken to determine the protective efficacy of bacille Calmette-Guérin (BCG) vaccination against tuberculosis (TB) disease. Results have shown that the protective efficacy of BCG ranges between 0% and 80%;^{1–3} efficacy is lower in tropical and subtropical latitudes with a high disease burden⁴ and due to exposure to non-tuberculous mycobacteria (NTM) or sunlight, or where there is a poor cold chain.⁵ In the 1950s, a Medical Research Council study in the United Kingdom, reported an 80% efficacy

Correspondence to: Soumya Swaminathan, National Institute for Research in Tuberculosis, No 1 Mayor Sathyamoorthy Road, Chetpet, Chennai 600 031, India. doctorsoumya@yahoo.com.

Conflicts of interest: none declared.

of BCG;¹ however, a study in South India conducted in the 1970s showed no protective efficacy.^{2,3} Among children, the protective efficacy of BCG against meningeal and miliary TB was 86% in randomised control trials and 75% in case-control studies.⁶ A 2006 meta-analysis yielded similar findings: 73% for tuberculous meningitis and 77% for miliary TB.⁷

There has been some discussion about whether BCG-vaccinated subjects have a lower risk of disease because the vaccine prevents tuberculous infection in uninfected persons, or whether it only lessens the risk of progression to disease in those infected. A 2014 meta-analysis in children, based on electronic database searches from 1950 to 2013, concluded that BCG offers both types of protection.⁸ This publication inspired us to retrospectively examine the data from one of our rural prevalence surveys⁹ to investigate the hypothesis that BCG prevents tuberculous infection in children. The study findings are reported here.

METHODOLOGY

A prevalence survey was undertaken in 1999–2001 in a random sample of 50 of 208 villages and 3 of 10 urban units in five *panchayat* unions (blocks), Ellapuram, Kadambathur, Poondi, Tiruvallur and Tiruvalangadu, in the BCG trial area of Tiruvallur District, Tamil Nadu, India.⁹ A cluster sampling design was adopted. All permanent residents aged ≥ 15 years in the selected clusters were questioned about chest symptoms and underwent chest radiography (CXR). Two sputum specimens, collected from those with abnormal CXR and/or chest symptoms, were examined using fluorescence microscopy and cultured on Löwenstein-Jensen medium; all positive culture specimens were subjected to identification tests. All children underwent the tuberculin skin test (TST) using 1 tuberculin unit (TU) (RT 23 with Tween 80). Full details have been published elsewhere.⁹

Definition of a TB case

A TB case was defined as a person with a positive culture, irrespective of sputum smear microscopy result.

Strain of BCG

All study subjects with a BCG scar received the Danish BCG strain 1331.

Definition of tuberculous infection

In 12 854 children aged < 10 years, the distribution of TST results with 1 TU RT 23 (with Tween 80) suggested an anti-mode of 12 mm. Using the ‘discrimination’ method described by Canetti et al.,¹⁰ a cut-off of 12 mm was chosen as it best discriminated between these children, relatively few of whom were likely to have been infected, and 472 confirmed cases of culture-positive TB. An induration of ≥ 12 mm was therefore taken as indicative of tuberculous infection.

Ranking of predictors

Unlike in the case of multiple linear regression, there is no universal agreement on how best to rank predictors, and several methods have been described in the literature.¹¹ Of these, ‘adequacy’, defined as the proportion of the full model log-likelihood that is explainable by

each predictor individually,¹² was chosen for ranking purposes in this paper, because it is analogous to the individual characteristic's contribution to the total R^2 (where R is the multiple correlation coefficient) in multiple linear regression. Three other methods were also investigated: logistic pseudo partial correlation, P value of the Wald χ^2 test and concordance statistics.

RESULTS

Influence of bacille Calmette-Guérin vaccination on tuberculin skin test sensitivity

Table 1 shows the association between the prevalence of TST positivity and various characteristics. Univariate analyses showed that the likelihood of a positive TST result increased substantially with age and the presence of a TB case in the household ($P < 0.0001$). Sex was not correlated ($P = 0.8$), but the presence of a BCG scar was associated with a lower prevalence of infection (12.2 vs. 14.7%, $P < 0.0001$). As these characteristics are interrelated, multivariate logistic regression was performed, which confirmed the importance of age and type of household (Table 2). However, the interaction between 1) age and type of household, and 2) age and BCG scar were both statistically significant. These findings suggested that separate analyses by BCG scar and age in households with/without a TB case would be more informative. The proportions of TST-positive patients in the various subgroups are given in Table 3.

In households with at least one TB case, the overall proportion of TST-positive patients was 35.5% in those without a BCG scar and 27.0% in those with a scar (Table 3), representing a reduction of 24% (95% confidence interval [CI] 0–48) in those who had received BCG ($P = 0.14$). However, a formal analysis of variance (not given here) showed that there was some evidence of an interaction between age and BCG. This led us to examine the effect of BCG in each of the three age groups. In children aged <5 years, the difference was significant (29.1% of 55 vs. 11.9% of 42, $P = 0.048$). In children aged 5–9 years, the corresponding proportions were 27.4% of 62 and 32.4% of 34 ($P = 0.6$), and in those aged 10–14 years the proportions were identical (both 45.8%) (Table 3).

In households with no TB case, the interaction between age and BCG was non-significant; the overall proportion of TST positivity in children aged 0–14 years was 14.3% of 9513 in children with no BCG scar compared to 12.0% of 6571 in children with a scar, a significant reduction ($P < 0.001$). However, those with a scar were substantially younger (38% vs. 24% aged <5 years, $P < 0.0001$); when this difference was taken into account, the direction of the difference was reversed, with the standardised percentages being lower—12.9% in those with no BCG scar and 14.3% in those with a scar. In all children aged <5 years, presence of BCG scar was associated with type of household ($P = 0.048$), which further confirmed that, as in this study, study findings in houses with/without a TB case should be examined separately. Our findings suggest that BCG has a protective effect against tuberculous infection in children aged <5 years, but only in households with recent exposure to TB.

Ranking of predictors

The ranking of various prognostic characteristics, as determined by the adequacy criterion, was as follows: age, type of household (with/without TB case), BCG scar (absence/presence) and sex; the corresponding contributions to total likelihood were respectively 8.82%, 0.60%, 0.17% and 0.0004%. The remaining three ranking methods investigated—logistic pseudo partial correlation, *P* value using Wald's χ^2 test and concordance statistic—confirmed first and second rank for age and type of household, but showed that the third and fourth ranks were interchangeable between BCG scar status and sex. Agreement between the four ranking methods was thus almost perfect (coefficient of concordance 0.90).

Analysis in other subsets

All analyses were performed in a representative sample of 16 384 children aged <15 years from 53 clusters. They were also performed in an additional 4805 children from the remaining 14 clusters in Tiruvelangadu and Kadambathur; thus findings from a total of 21 189 children from 67 clusters were examined. These confirmed the conclusions reported above, and in particular, the difference between children with and without a BCG scar in households with at least one TB case, 34.8% of 230 vs. 28.5% of 123, a reduction of 18% (95% CI 0–41) in children who had received BCG (*P* = 0.23).

DISCUSSION

Retrospective analysis of the data from the rural prevalence survey⁹ showed that in households with a TB case, 29.1% of 55 children aged <5 years without a BCG scar were TST-positive compared to 11.9% of 42 children with a BCG scar, a reduction of 59%. In all children aged <15 years, the corresponding proportions were 35.5% and 27.0%, and the difference was 24% (95% CI 0–48). As the two groups were not obtained using random sampling, it could be argued that the lower prevalence of infection in those with a BCG scar may be because parents who chose to have their children BCG-vaccinated were economically better off and more knowledgeable about health risks to children. Another limitation in attributing the reduction in infection to BCG vaccination per se was that our definition of infection was based on the outcome of the standard TST, which does not distinguish between infection by *Mycobacterium tuberculosis* and that caused by BCG vaccination or infection due to NTM. In a country with a policy of BCG vaccination at birth and a notable prevalence of NTM infection,¹³ their impact may have had a confounding effect.

A recently developed technique, the T-cell-based interferon-gamma release assay (IGRA), has the capacity to detect tuberculous infection and, more importantly, distinguish it from previous BCG vaccination and most NTM infections. Based on the outcome of IGRAs, a meta-analysis of 14 studies including 3855 participants demonstrated a protective effect of 19% (95% CI 8–29) against tuberculous infection in participants aged 15 years who had had recent exposure to TB patients;¹³ in a subset of five studies involving 1862 children who were simultaneously exposed to a single well-defined source, BCG efficacy was slightly higher, at 28% (95% CI 0–48). The corresponding estimate from our study was similar, at 24%.

Our finding that the BCG vaccine protects against tuberculous infection in children is consistent with a previous publication from Turkey that yielded an odds ratio of 0.60 (95% CI 0.43–0.83) for tuberculous infection compared with non-vaccinated children.¹⁴

Cost and complexity may make it difficult to use IGRAs in public health interventions. An attractive alternative could be the C-Tb skin test, developed by the Statens Serum Institute, Copenhagen, Denmark, which has been reported to be more specific than the TST.¹⁵

CONCLUSION

We believe that more studies on this subject are necessary with IGRAs and C-Tb skin tests in addition to, rather than instead of, the TST, in keeping with World Health Organization guidelines for latent tuberculous infection.¹⁶ Future trials of TB vaccines, especially in children, should include a component of protection against tuberculous infection in the outcome assessment, in addition to reduction in disease incidence.

Acknowledgments

The authors thank all field staff, all Bacteriology Department, Statistics, Electronic Data Processing Division and Administration personnel, and the anonymous reviewers for their valuable feedback that improved this paper.

The survey was supported in part by the World Health Organization, with financial assistance from the United States Agency for International Development under the Model DOTS Project.

References

1. Medical Research Council. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Fourth report to the Medical Research Council by its Tuberculosis Vaccines Clinical Trials Committee. *Bull World Health Organ.* 1972; 46:371–385. [PubMed: 4537855]
2. Baily GV. Trial of BCG vaccines in south India for tuberculosis prevention. *Indian J Med Res.* 1980; 72(Suppl):S1–S74.
3. Tuberculosis Research Centre, Chennai. Fifteen-year follow-up of trial of BCG vaccines in south India for tuberculosis prevention. *Indian J Med Res.* 1999; 110:56–69. [PubMed: 10573656]
4. Zelner JL, Murray MB, Becerra MC, et al. Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis. *Am J Respir Crit Care Med.* 2014; 189:853–859. [PubMed: 24592878]
5. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. *Lancet.* 1995; 346:1339–1345. [PubMed: 7475776]
6. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. *Int J Epidemiol.* 1993; 22:1154–1158. [PubMed: 8144299]
7. Trunz BB, Fine PEM, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost effectiveness. *Lancet.* 2006; 367:1173–1180. [PubMed: 16616560]
8. Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against *Mycobacterium tuberculosis* infection in children: systematic review and meta-analysis. *BMJ.* 2014; 349:g4643. [PubMed: 25097193]
9. Gopi PG, Subramani R, Radhakrishna S, et al. A baseline survey of the prevalence of tuberculosis in a community in south India at the commencement of a DOTS programme. *Int J Tuberc Lung Dis.* 2003; 7:1154–1162. [PubMed: 14677890]

10. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969; 41:21–43. [PubMed: 5309084]
11. Thompson, D. Ranking predictors in logistic regression. Milwaukee, WI, USA: Assurant Health; 2009. www.mwsug.org/proceedings/2009/stats/MWSUG-2009-D10. Accessed January 2017
12. Harrell, F. Regression model strategies. New York, NY, USA: Springer; 2001.
13. Narain R, Ananthakrishnan DS, Diwakara AM. Prevalence of non-specific tuberculin sensitivity in certain parts of India. Bull World Health Organ. 1974; 51:271–278.
14. Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of *Mycobacterium tuberculosis* infection in children with household tuberculosis contact: a prospective community-based study. Lancet. 2005; 366:1443–1451. [PubMed: 16243089]
15. Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of *M. tuberculosis* infection. PLOS ONE. 2013; 8:e64215. [PubMed: 23691171]
16. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland: WHO; 2014. WHO/HTM/TB/2015.01

Table 1

Univariate correlates of tuberculin skin test positivity in children

Characteristic	Subjects <i>n</i>	Infected <i>n</i> (%)	<i>P</i> value
Age, years			<0.0001*
0–4	4 897	172 (3.5)	
5–9	5 686	674(11.9)	
10–14	5 801	1 399 (24.1)	
Sex			0.83
Female	8 034	1 096 (13.6)	
Male	8 350	1 149 (13.8)	
BCG scar			<0.0001
Absent	9 713	1 428 (14.7)	
Present	6 671	817 (12.2)	
Type of household			<0.0001
No TB case	16 084	2 147 (13.3)	
≥1 TB case	300	98 (32.7)	
Total	16 384	2 245 (13.7)	

*Based on trend χ^2 with 1 degree of freedom. BCG = bacille Calmette-Guérin; TB = tuberculosis.

Table 2

Univariate and multivariate ORs for age, sex, BCG scar and presence of a TB case in the household

Characteristic	Subjects <i>n</i>	Univariate OR	aOR (95%CI)	<i>P</i> value
Age, years				
0–4	4 897	1.00	1.00	
5–9	5 686	3.69	3.89 (3.20–4.73)	<0.0001
10–14	5 801	8.73	9.1 (7.62–10.87)	<0.0001
Sex				
Male	8 350	1.01	1.04 (0.95–1.14)	0.42
Female	8 034	1.00	1.00	
BCG scar				
Absent	9 713	1.00	1.00	
Present	6 671	0.81	0.91 (0.66–1.24)	0.55
Type of household				
No TB case	16 084	1.00	1.00	
≥1 TB case	300	3.15	8.51 (5.11–14.16)	<0.0001
Interaction age × BCG scar				
BCG scar				
0–4 years			1.00	
5–9 years			1.08	0.32
10–14 years			1.19	0.01
Interaction age × type of household				
≥1 TB case				
0–4 years			1.00	
5–9 years			0.37	0.004
10–14 years			0.32	0.001
Interaction BCG scar × type of household				
≥ 1 TB case				
No scar			1.00	
Scar			0.75	0.30
Goodness-of-fit (Hosmer-Lemeshow χ^2)				
		0.01	4 df	1.00
Overall correct predictions				
				86%

OR = odds ratio; BCG = bacille Calmette-Guérin; TB = tuberculosis; aOR = adjusted OR; CI = confidence interval; df = degrees of freedom.

Table 3
TST positivity related to type of household, age and presence of BCG scar in children

Group	Age years	Children with BCG scar			Children with no BCG scar			All children		
		Total n	n	% (a)	Total n	n	% (b)	Total n	TST-positive n (%)	Reduction due to BCG (b - a)
Households with at least 1 TB case										
	0-4	42	5	11.9	55	16	29.1	97	21 (21.6)	17.2
	5-9	34	11	32.4	62	17	27.4	96	28 (29.2)	-4.9
	10-14	24	11	45.8	83	38	45.8	107	49 (45.8)	-0.1
	Total	100	27	27.0	200	71	35.5	300	98 (32.7)	8.5
Households with no TB case										
	0-4	2 507	78	3.1	2 293	73	3.2	4 800	151 (3.1)	0.1
	5-9	2 458	294	12.0	3 132	352	11.2	5 590	646 (11.6)	-0.7
	10-14	1 606	418	26.0	4 088	932	22.8	5 694	1 350 (23.7)	-3.2
	Total	6 571	790	12.0	9 513	1 357	14.3	16 084	2 147 (13.3)	2.2
All households										
	0-4	2 549	83	3.3	2 348	89	3.8	4 897	172 (3.5)	0.5
	5-9	2 492	305	12.2	3 194	369	11.6	5 686	674 (11.9)	-0.7
	10-14	1 630	429	26.3	4 171	970	23.3	5 801	1 399 (24.1)	-3.1
	Total	6 671	817	12.2	9 713	1 428	14.7	16 384	2 245 (13.7)	2.5

TST = tuberculin skin test; BCG = bacille Calmette-Guérin; TB = tuberculosis.